Actinogen Medical reported steady progress in its Phase 2b/3 XanaMIA trial for Alzheimer’s disease, with topline results expected in November 2026. The trial is fully enrolled with 247 participants, and an independent safety review has approved continuation without changes. The company also has strong patient participation in an open-label extension to gather longer-term data. With $16.7 million in cash, Actinogen is funded into mid-2027, supported by potential tax rebates and option exercises. Positive depression trial data further validate their drug Xanamem. The November readout is a key upcoming catalyst that could validate Xanamem as a once-daily oral treatment for mild to moderate Alzheimer’s, advancing regulatory and commercial prospects.
Investors are rotating capital into frontier tech stocks such as SpaceX, Anthropic, and OpenAI, anticipating their upcoming IPOs and signaling a shift from legacy tech giants. The FAB 10 and MANGOS baskets highlight this trend, with SpaceX's $75 bill...
Zcash mining currently generates about $708 per megawatt-hour (MWh) of electricity, nearly four times the $179 per MWh earned by Bitcoin mining with comparable equipment. This higher gross revenue is driving new miners and institutional players to Zc...
Oracle reported a strong quarter, surpassing revenue and earnings per share expectations driven by accelerating cloud infrastructure growth and strong AI demand. Despite a 770 basis point year-over-year gross margin decline and negative free cash flo...
On the 25th anniversary of 9/11, billionaire John Catsimatidis warned that countries like Russia, North Korea, China, and Iran are actively trying to undermine President Donald Trump ahead of the November election. He expressed disappointment with Ca...
Lakeland Industries remains a Buy, but the price target was lowered from $18.00 to $14.50 due to revised margin expectations and increased litigation risk from new PFAS multidistrict lawsuits. While gross margin improved to 37%, only half of that is ...
